Moving away from amyloid beta to move on in Alzheimer research

20Citations
Citations of this article
68Readers
Mendeley users who have this article in their library.

Abstract

Alzheimer's disease (AD) is characterized by a progressive decay of cognitive abilities, most remarkably (spatial) memory and learning. AD is diagnosed by clinical mental tests, often combined with the detection of neurobiological markers, mainly brain imaging studies and a decreased amyloid beta (Aß) level and/or increased total and hyper-phosphorylated Tau protein (tau-P) in cerebral spinal fluid (Hampel et al., 2008; Alzheimer's Association, 2014). The diagnosis is confirmed post-mortem by histopathological detection of senile plaques, composed of Aß accumulations, and tau-P-containing neurofibrillary tangles (Jellinger and Bancher, 1998). However, non-demented, aged patients may have a histopathology that is indistinguishable from AD (Price and Morris, 1999; Nelson et al., 2012). Furthermore, the brains of AD may have additional changes, such as (micro)vascular changes (Scheibel et al., 1989; de la Torre, 2002; Bell and Zlokovic, 2009; Hommet et al., 2011), white matter hyperintensities (Kandiah et al., 2015), and vacuolar cells, which are not considered as pathognomonic features under current standards (Nelson et al., 2012).

Cite

CITATION STYLE

APA

Moreno-Treviño, M. G., Castillo-López, J., & Meester, I. (2015). Moving away from amyloid beta to move on in Alzheimer research. Frontiers in Aging Neuroscience, 7(JAN). https://doi.org/10.3389/fnagi.2015.00002

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free